Every 424B that Can-Fite BioPharma Ltd. (CANF) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CANF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CANF filings page.
Can-Fite BioPharma Ltd. (CANF) registered for resale up to 6,589,796 ordinary shares represented by 3,294,898 ADSs, issuable upon exercise of New Warrants and Placement Agent Warrants. This is a selling-shareholder resale; Can-Fite will not receive proceeds from those resales. It may receive proceeds from cash exercises, with approximately $8.31 million if all the warrants are exercised for cash in full; the company says any net proceeds would fund research and development, general and administrative expenses, and working capital.
The registered amount comprises 6,366,952 ordinary shares represented by 3,183,476 ADSs issuable under New Warrants, and 222,844 ordinary shares represented by 111,422 ADSs issuable under Placement Agent Warrants. Ordinary shares outstanding were 6,063,093 as of September 25, 2026. Warrant exercises are subject to a 4.99% or 9.99% beneficial-ownership limit; an increase in that limit is not effective until 61 days after notice. Can-Fite states that sales of substantial amounts could adversely affect the market price of its ordinary shares and ADSs.
Can-Fite BioPharma Ltd. filed a prospectus registering for resale up to 3,294,898 ordinary shares represented by 1,647,449 ADSs, consisting primarily of shares issuable upon exercise of repriced warrants. The offering is by selling shareholders; the company will receive proceeds only if warrants are exercised for cash. The ADS ratio is 2 ordinary shares per ADS and there are 4,285,093 ordinary shares outstanding as of March 30, 2026.
Can-Fite Biopharma Ltd. is updating its Form F-1 registration (Registration No. 333-288890) via a prospectus supplement dated March 5, 2026 to cover up to 1,250,000 American Depositary Shares (representing 2,500,000 ordinary shares) and related warrants and pre-funded warrants.
The supplement incorporates a Form 6-K describing an inducement arrangement: a holder agreed to exercise 795,869 Existing Warrants for cash at a reduced price of $5.00 per ADS, yielding approximately $4.0 million gross proceeds, and the Company will issue New Warrants to purchase 1,591,738 ADSs at $5.00. The Company engaged H.C. Wainwright as placement agent with a 7.0% cash fee, a 1.0% management fee and Placement Agent Warrants to purchase 55,711 ADSs at an exercise price of $6.25. The closing was expected on or about March 5, 2026, and the Company agreed to file a resale registration statement and use commercially reasonable efforts to have it declared effective within 90 days.